Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.
about
The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.Getting to 90-90-90 in paediatric HIV: What is needed?Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.Pharmacotherapy of pediatric HIV infection
P2860
Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.
@ast
Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.
@en
type
label
Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.
@ast
Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.
@en
prefLabel
Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.
@ast
Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.
@en
P2093
P2860
P1476
Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.
@en
P2093
E Capparelli
M Mirochnick
R S Sperling
R van Dyke
S A Spector
P2860
P304
P407
P577
1998-04-01T00:00:00Z